Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: February 21, 2026, 1:09 pm
Author: Getaka|Social: XLinkedIn
Stock Ticker - BSE: 526953 | NSE: VENUSREM

Venus Remedies Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: February 21, 2026, 1:09 pm

Market Cap 1,015 Cr.
Current Price 759
Intrinsic Value₹385.73
High / Low 873/278
Stock P/E13.3
Book Value 445
Dividend Yield0.00 %
ROCE11.1 %
ROE7.16 %
Face Value 10.0
PEG Ratio1.15

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Venus Remedies Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Lactose (India) Ltd 122 Cr. 97.0 137/84.325.3 49.60.00 %12.9 %9.69 % 10.0
MPS Pharmaa Ltd 3.21 Cr. 1.68 4.02/1.68 0.330.00 %9.79 %59.0 % 10.0
Gujarat Themis Biosyn Ltd 3,659 Cr. 336 479/20876.6 24.30.20 %27.3 %21.7 % 1.00
Gujarat Terce Laboratories Ltd 29.9 Cr. 40.3 79.8/37.2 10.60.00 %41.4 %14.6 % 10.0
Gujarat Inject (Kerala) Ltd 90.8 Cr. 62.0 62.2/17.0363 6.930.00 %13.5 %11.0 % 10.0
Industry Average20,113.48 Cr1,087.7357.00201.330.37%16.29%15.20%6.10

All Competitor Stocks of Venus Remedies Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 11715695168143195109170177195137193180
Expenses 1091318515013117697163158166122162143
Operating Profit 825101812191181829153138
OPM % 7%16%11%11%8%10%10%4%10%15%11%16%21%
Other Income 43232428127323
Interest 0000000000000
Depreciation 7886766655667
Profit before tax 520514817792531132633
Tax % 28%44%77%31%12%40%82%61%21%32%24%24%24%
Net Profit 311110711142021102026
EPS in Rs 2.468.270.887.445.127.860.912.6314.6615.717.1815.0619.14

Last Updated: February 3, 2026, 4:16 pm

Below is a detailed analysis of the quarterly data for Venus Remedies Ltd based on the most recent figures (Dec 2025) and their trends compared to the previous period:

  • For Sales, as of Dec 2025, the value is 180.00 Cr.. The value appears to be declining and may need further review. It has decreased from 193.00 Cr. (Sep 2025) to 180.00 Cr., marking a decrease of 13.00 Cr..
  • For Expenses, as of Dec 2025, the value is 143.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 162.00 Cr. (Sep 2025) to 143.00 Cr., marking a decrease of 19.00 Cr..
  • For Operating Profit, as of Dec 2025, the value is 38.00 Cr.. The value appears strong and on an upward trend. It has increased from 31.00 Cr. (Sep 2025) to 38.00 Cr., marking an increase of 7.00 Cr..
  • For OPM %, as of Dec 2025, the value is 21.00%. The value appears strong and on an upward trend. It has increased from 16.00% (Sep 2025) to 21.00%, marking an increase of 5.00%.
  • For Other Income, as of Dec 2025, the value is 3.00 Cr.. The value appears strong and on an upward trend. It has increased from 2.00 Cr. (Sep 2025) to 3.00 Cr., marking an increase of 1.00 Cr..
  • For Interest, as of Dec 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 0.00 Cr..
  • For Depreciation, as of Dec 2025, the value is 7.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 6.00 Cr. (Sep 2025) to 7.00 Cr., marking an increase of 1.00 Cr..
  • For Profit before tax, as of Dec 2025, the value is 33.00 Cr.. The value appears strong and on an upward trend. It has increased from 26.00 Cr. (Sep 2025) to 33.00 Cr., marking an increase of 7.00 Cr..
  • For Tax %, as of Dec 2025, the value is 24.00%. The value remains steady. There is no change compared to the previous period (Sep 2025) which recorded 24.00%.
  • For Net Profit, as of Dec 2025, the value is 26.00 Cr.. The value appears strong and on an upward trend. It has increased from 20.00 Cr. (Sep 2025) to 26.00 Cr., marking an increase of 6.00 Cr..
  • For EPS in Rs, as of Dec 2025, the value is 19.14. The value appears strong and on an upward trend. It has increased from 15.06 (Sep 2025) to 19.14, marking an increase of 4.08.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: December 15, 2025, 4:25 am

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 531455407400372322335544597552596640702
Expenses 393366326349333289295490535492537577608
Operating Profit 138898151393341546260606494
OPM % 26%20%20%13%11%10%12%10%10%11%10%10%13%
Other Income 01222-3-443810123124
Interest 294138343525131300000
Depreciation 40464240343432353432262322
Profit before tax 6934-22-28-30-8493638457295
Tax % 7%-95%52%-21%11%-4%24%-27%-12%30%36%37%
Net Profit 6452-17-31-29-10624127284570
EPS in Rs 56.204.511.49-13.84-24.87-23.15-8.1050.0530.4619.8821.3133.9052.61
Dividend Payout % 0%0%0%0%0%0%0%0%0%0%0%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)-92.19%-60.00%-950.00%-82.35%6.45%65.52%720.00%-33.87%-34.15%3.70%60.71%
Change in YoY Net Profit Growth (%)0.00%32.19%-890.00%867.65%88.80%59.07%654.48%-753.87%-0.28%37.85%57.01%

Venus Remedies Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:3%
5 Years:14%
3 Years:2%
TTM:9%
Compounded Profit Growth
10 Years:22%
5 Years:69%
3 Years:-3%
TTM:64%
Stock Price CAGR
10 Years:15%
5 Years:36%
3 Years:30%
1 Year:31%
Return on Equity
10 Years:2%
5 Years:8%
3 Years:6%
Last Year:7%

Last Updated: September 5, 2025, 1:51 pm

Balance Sheet

Last Updated: December 4, 2025, 2:11 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 11111112121212121313131313
Reserves 450445426376350320311388427447474548581
Borrowings 28932133531230729822051434241214
Other Liabilities 8464706582102100104979898153159
Total Liabilities 834841843765751733644556580601627716768
Fixed Assets 439444452406389364289262241216219229237
CWIP 68788066656525252526212634
Investments 000000000201984193
Other Assets 327319310293297304330269314339368376303
Total Assets 834841843765751733644556580601627716768

Below is a detailed analysis of the balance sheet data for Venus Remedies Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2025, the value is 13.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 13.00 Cr..
  • For Reserves, as of Sep 2025, the value is 581.00 Cr.. The value appears strong and on an upward trend. It has increased from 548.00 Cr. (Mar 2025) to 581.00 Cr., marking an increase of 33.00 Cr..
  • For Borrowings, as of Sep 2025, the value is 14.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 2.00 Cr. (Mar 2025) to 14.00 Cr., marking an increase of 12.00 Cr..
  • For Other Liabilities, as of Sep 2025, the value is 159.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 153.00 Cr. (Mar 2025) to 159.00 Cr., marking an increase of 6.00 Cr..
  • For Total Liabilities, as of Sep 2025, the value is 768.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 716.00 Cr. (Mar 2025) to 768.00 Cr., marking an increase of 52.00 Cr..
  • For Fixed Assets, as of Sep 2025, the value is 237.00 Cr.. The value appears strong and on an upward trend. It has increased from 229.00 Cr. (Mar 2025) to 237.00 Cr., marking an increase of 8.00 Cr..
  • For CWIP, as of Sep 2025, the value is 34.00 Cr.. The value appears strong and on an upward trend. It has increased from 26.00 Cr. (Mar 2025) to 34.00 Cr., marking an increase of 8.00 Cr..
  • For Investments, as of Sep 2025, the value is 193.00 Cr.. The value appears strong and on an upward trend. It has increased from 84.00 Cr. (Mar 2025) to 193.00 Cr., marking an increase of 109.00 Cr..
  • For Other Assets, as of Sep 2025, the value is 303.00 Cr.. The value appears to be declining and may need further review. It has decreased from 376.00 Cr. (Mar 2025) to 303.00 Cr., marking a decrease of 73.00 Cr..
  • For Total Assets, as of Sep 2025, the value is 768.00 Cr.. The value appears strong and on an upward trend. It has increased from 716.00 Cr. (Mar 2025) to 768.00 Cr., marking an increase of 52.00 Cr..

Notably, the Reserves (581.00 Cr.) exceed the Borrowings (14.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 5368475931457813241373786
Cash from Investing Activity + -95-673-188-11-557-17-58-8-77
Cash from Financing Activity + 40-1-46-44-39-35-73-162-9-1-1-1
Net Cash Flow -2-13-40-1-02714-22289

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-151.00-232.00-254.00-261.00-268.00-265.00-179.003.0019.0018.0019.0062.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 455155434643332124514964
Inventory Days 17319421922624628629612911813212597
Days Payable 384038485272777647565589
Cash Conversion Cycle 180204236221240257252749512712072
Working Capital Days 3954695425-173718210911886
ROCE %14%6%5%2%1%1%2%8%8%8%9%11%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 41.76%41.76%41.76%41.76%41.76%41.76%41.76%41.76%41.76%41.76%41.76%41.76%
FIIs 1.00%0.98%1.03%1.59%1.48%1.06%1.18%1.11%1.34%2.25%1.86%2.25%
DIIs 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.11%0.75%1.03%
Public 57.26%57.26%57.21%56.65%56.76%57.17%57.06%57.13%56.90%55.89%55.62%54.95%
No. of Shareholders 21,71920,49819,26719,56019,91319,61419,55719,77119,98219,30717,72518,606

Shareholding Pattern Chart

No. of Shareholders

Venus Remedies Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 10.0010.0010.0010.0010.00
Basic EPS (Rs.) 33.9021.3119.8830.8650.04
Diluted EPS (Rs.) 33.9021.3119.8830.8650.04
Cash EPS (Rs.) 50.7441.1044.0455.5578.63
Book Value[Excl.RevalReserv]/Share (Rs.) 419.65364.74344.38329.50324.33
Book Value[Incl.RevalReserv]/Share (Rs.) 419.65364.74344.38329.50324.33
Revenue From Operations / Share (Rs.) 484.69449.95415.58447.86444.11
PBDIT / Share (Rs.) 63.2053.2552.7652.6859.48
PBIT / Share (Rs.) 46.3733.4728.6027.6030.90
PBT / Share (Rs.) 53.7333.4028.3827.2439.34
Net Profit / Share (Rs.) 33.9021.3119.8730.4750.04
NP After MI And SOA / Share (Rs.) 33.9021.3119.8730.4750.04
PBDIT Margin (%) 13.0411.8312.6911.7613.39
PBIT Margin (%) 9.567.436.886.166.95
PBT Margin (%) 11.087.426.826.088.85
Net Profit Margin (%) 6.994.734.786.8011.26
NP After MI And SOA Margin (%) 6.994.734.786.8011.26
Return on Networth / Equity (%) 8.075.845.779.2415.43
Return on Capital Employeed (%) 10.698.177.377.578.31
Return On Assets (%) 6.334.544.417.0211.11
Long Term Debt / Equity (X) 0.000.070.080.080.11
Total Debt / Equity (X) 0.000.080.090.090.12
Asset Turnover Ratio (%) 0.960.970.901.010.86
Current Ratio (X) 3.314.533.913.002.38
Quick Ratio (X) 2.582.992.461.641.15
Inventory Turnover Ratio (X) 5.832.852.653.042.64
Interest Coverage Ratio (X) 1291.82759.66239.55146.415.64
Interest Coverage Ratio (Post Tax) (X) 542.31305.0691.2485.673.94
Enterprise Value (Cr.) 322.06409.53205.06351.82361.07
EV / Net Operating Revenue (X) 0.490.680.360.580.65
EV / EBITDA (X) 3.815.752.915.004.92
MarketCap / Net Operating Revenue (X) 0.610.720.380.600.61
Price / BV (X) 0.710.890.470.810.84
Price / Net Operating Revenue (X) 0.610.720.380.600.61
EarningsYield 0.110.060.120.110.18

After reviewing the key financial ratios for Venus Remedies Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
  • For Basic EPS (Rs.), as of Mar 25, the value is 33.90. This value is within the healthy range. It has increased from 21.31 (Mar 24) to 33.90, marking an increase of 12.59.
  • For Diluted EPS (Rs.), as of Mar 25, the value is 33.90. This value is within the healthy range. It has increased from 21.31 (Mar 24) to 33.90, marking an increase of 12.59.
  • For Cash EPS (Rs.), as of Mar 25, the value is 50.74. This value is within the healthy range. It has increased from 41.10 (Mar 24) to 50.74, marking an increase of 9.64.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 419.65. It has increased from 364.74 (Mar 24) to 419.65, marking an increase of 54.91.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 419.65. It has increased from 364.74 (Mar 24) to 419.65, marking an increase of 54.91.
  • For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 484.69. It has increased from 449.95 (Mar 24) to 484.69, marking an increase of 34.74.
  • For PBDIT / Share (Rs.), as of Mar 25, the value is 63.20. This value is within the healthy range. It has increased from 53.25 (Mar 24) to 63.20, marking an increase of 9.95.
  • For PBIT / Share (Rs.), as of Mar 25, the value is 46.37. This value is within the healthy range. It has increased from 33.47 (Mar 24) to 46.37, marking an increase of 12.90.
  • For PBT / Share (Rs.), as of Mar 25, the value is 53.73. This value is within the healthy range. It has increased from 33.40 (Mar 24) to 53.73, marking an increase of 20.33.
  • For Net Profit / Share (Rs.), as of Mar 25, the value is 33.90. This value is within the healthy range. It has increased from 21.31 (Mar 24) to 33.90, marking an increase of 12.59.
  • For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 33.90. This value is within the healthy range. It has increased from 21.31 (Mar 24) to 33.90, marking an increase of 12.59.
  • For PBDIT Margin (%), as of Mar 25, the value is 13.04. This value is within the healthy range. It has increased from 11.83 (Mar 24) to 13.04, marking an increase of 1.21.
  • For PBIT Margin (%), as of Mar 25, the value is 9.56. This value is below the healthy minimum of 10. It has increased from 7.43 (Mar 24) to 9.56, marking an increase of 2.13.
  • For PBT Margin (%), as of Mar 25, the value is 11.08. This value is within the healthy range. It has increased from 7.42 (Mar 24) to 11.08, marking an increase of 3.66.
  • For Net Profit Margin (%), as of Mar 25, the value is 6.99. This value is within the healthy range. It has increased from 4.73 (Mar 24) to 6.99, marking an increase of 2.26.
  • For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.99. This value is below the healthy minimum of 8. It has increased from 4.73 (Mar 24) to 6.99, marking an increase of 2.26.
  • For Return on Networth / Equity (%), as of Mar 25, the value is 8.07. This value is below the healthy minimum of 15. It has increased from 5.84 (Mar 24) to 8.07, marking an increase of 2.23.
  • For Return on Capital Employeed (%), as of Mar 25, the value is 10.69. This value is within the healthy range. It has increased from 8.17 (Mar 24) to 10.69, marking an increase of 2.52.
  • For Return On Assets (%), as of Mar 25, the value is 6.33. This value is within the healthy range. It has increased from 4.54 (Mar 24) to 6.33, marking an increase of 1.79.
  • For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.07 (Mar 24) to 0.00, marking a decrease of 0.07.
  • For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.08 (Mar 24) to 0.00, marking a decrease of 0.08.
  • For Asset Turnover Ratio (%), as of Mar 25, the value is 0.96. It has decreased from 0.97 (Mar 24) to 0.96, marking a decrease of 0.01.
  • For Current Ratio (X), as of Mar 25, the value is 3.31. This value exceeds the healthy maximum of 3. It has decreased from 4.53 (Mar 24) to 3.31, marking a decrease of 1.22.
  • For Quick Ratio (X), as of Mar 25, the value is 2.58. This value exceeds the healthy maximum of 2. It has decreased from 2.99 (Mar 24) to 2.58, marking a decrease of 0.41.
  • For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.83. This value is within the healthy range. It has increased from 2.85 (Mar 24) to 5.83, marking an increase of 2.98.
  • For Interest Coverage Ratio (X), as of Mar 25, the value is 1,291.82. This value is within the healthy range. It has increased from 759.66 (Mar 24) to 1,291.82, marking an increase of 532.16.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 542.31. This value is within the healthy range. It has increased from 305.06 (Mar 24) to 542.31, marking an increase of 237.25.
  • For Enterprise Value (Cr.), as of Mar 25, the value is 322.06. It has decreased from 409.53 (Mar 24) to 322.06, marking a decrease of 87.47.
  • For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.49. This value is below the healthy minimum of 1. It has decreased from 0.68 (Mar 24) to 0.49, marking a decrease of 0.19.
  • For EV / EBITDA (X), as of Mar 25, the value is 3.81. This value is below the healthy minimum of 5. It has decreased from 5.75 (Mar 24) to 3.81, marking a decrease of 1.94.
  • For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.61. This value is below the healthy minimum of 1. It has decreased from 0.72 (Mar 24) to 0.61, marking a decrease of 0.11.
  • For Price / BV (X), as of Mar 25, the value is 0.71. This value is below the healthy minimum of 1. It has decreased from 0.89 (Mar 24) to 0.71, marking a decrease of 0.18.
  • For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.61. This value is below the healthy minimum of 1. It has decreased from 0.72 (Mar 24) to 0.61, marking a decrease of 0.11.
  • For EarningsYield, as of Mar 25, the value is 0.11. This value is below the healthy minimum of 5. It has increased from 0.06 (Mar 24) to 0.11, marking an increase of 0.05.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Venus Remedies Ltd as of February 22, 2026 is: ₹345.79

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of February 22, 2026, Venus Remedies Ltd is Overvalued by 54.44% compared to the current share price ₹759.00

Intrinsic Value of Venus Remedies Ltd as of February 22, 2026 is: ₹385.73

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of February 22, 2026, Venus Remedies Ltd is Overvalued by 49.18% compared to the current share price ₹759.00

Last 5 Year EPS CAGR: 11.55%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The company has higher reserves (426.38 cr) compared to borrowings (175.00 cr), indicating strong financial stability.
  2. The company has shown consistent growth in sales (496.38 cr) and profit (24.85 cr) over the years.
  1. The stock has a low average ROCE of 6.25%, which may not be favorable.
  2. The stock has a high average Working Capital Days of 64.92, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 173.17, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Venus Remedies Ltd:
    1. Net Profit Margin: 6.99%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 10.69% (Industry Average ROCE: 16.29%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 8.07% (Industry Average ROE: 15.2%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 542.31
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 2.58
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 13.3 (Industry average Stock P/E: 57)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Venus Remedies Ltd. is a Public Limited Listed company incorporated on 15/09/1989 and has its registered office in the State of Chandigarh, India. Company's Corporate Identification Number(CIN) is L24232CH1989PLC009705 and registration number is 009705. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 639.46 Cr. and Equity Capital is Rs. 13.37 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsS.C.O. 857, C. No. 10, 2nd Floor, NAC Manimajra, Chandigarh Chandigarh 160101Contact not found
Management
NamePosition Held
Mr. Pawan ChaudharyChairman & Managing Director
Dr.(Mrs.) Manu ChaudharyJoint Managing Director
Mr. Peeyush JainDeputy Managing Director
Mr. Ashutosh JainExecutive Director
Mr. Akshansh ChaudharyExecutive Director
Dr.(Mrs.) Savita GuptaIndependent Director
Mr. N P S MongaIndependent Director
Mr. Navdeep SudIndependent Director
Mr. Jagdish Chander SharmaIndependent Director
Dr. Anil KumarIndependent Director

FAQ

What is the intrinsic value of Venus Remedies Ltd?

Venus Remedies Ltd's intrinsic value (as of 22 February 2026) is ₹385.73 which is 49.18% lower the current market price of ₹759.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,015 Cr. market cap, FY2025-2026 high/low of ₹873/278, reserves of ₹581 Cr, and liabilities of ₹768 Cr.

What is the Market Cap of Venus Remedies Ltd?

The Market Cap of Venus Remedies Ltd is 1,015 Cr..

What is the current Stock Price of Venus Remedies Ltd as on 22 February 2026?

The current stock price of Venus Remedies Ltd as on 22 February 2026 is ₹759.

What is the High / Low of Venus Remedies Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Venus Remedies Ltd stocks is ₹873/278.

What is the Stock P/E of Venus Remedies Ltd?

The Stock P/E of Venus Remedies Ltd is 13.3.

What is the Book Value of Venus Remedies Ltd?

The Book Value of Venus Remedies Ltd is 445.

What is the Dividend Yield of Venus Remedies Ltd?

The Dividend Yield of Venus Remedies Ltd is 0.00 %.

What is the ROCE of Venus Remedies Ltd?

The ROCE of Venus Remedies Ltd is 11.1 %.

What is the ROE of Venus Remedies Ltd?

The ROE of Venus Remedies Ltd is 7.16 %.

What is the Face Value of Venus Remedies Ltd?

The Face Value of Venus Remedies Ltd is 10.0.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Venus Remedies Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports